All In Biotech

Drug Trial Radar · NCT03297502

Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis

Multicenter Study of the Safety and Bioequivalence of Par's Pimecrolimus Cream, 1% and RLD Elidel® (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in Treatment of Mild to Moderate Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Sep 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 582 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

582

Actual

Start

Jun 2016

Primary completion

Jun 2017

Study completion Jun 2017

Sponsor

Lead sponsor
Par Pharmaceutical, Inc.Industry
Sponsor type
Industry
First posted
Sep 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 3, double-blind, randomized, parallel-group, placebo-controlled, multicenter study to evaluate the safety and bioequivalence of Par Pharmaceutical Inc.'s Pimecrolimus Cream, 1% and Reference Listed Elidel® (Pimecrolimus Cream, 1%). The study compares both active treatments to a placebo control in the treatment of mild to moderate atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • pimecrolimus cream 1%Drug

  • Elidel (pimecrolimus) cream 1%Drug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with treatment success in each treatment groupTime frame: Day 15

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.